|
Session 38
Oral Abstracts
Drug Delivery, Interactions and Genetic Variability
Wednesday, 10 am-12 noon
Room: Ballroom B/C |
| 10:00 am 131 |
Low Tenofovir Concentrations in Cerebrospinal Fluid
Brookie Best*1, S Letendre1, P Koopmans2, D Clifford3, A Collier4, B Gelman5, J McArthur6, D Simpson7, E Capparelli1, R Ellis1, and the CHARTER Group
1Univ of California, San Diego, US; 2Radboud Univ Nijmegen Med Ctr, The Netherlands; 3Washington Univ, St Louis, MO, US; 4Univ of Washington, Seattle, US; 5Univ of Texas Med Branch, Galveston, US; 6Johns Hopkins Univ, Baltimore, MD, US; and 7Mt Sinai Sch of Med, New York, NY, US |
| 10:15 am 132 |
Drug Interaction between Antimalarial Drugs and Lopinavir/Ritonavir
Polina German*1, S Parikh2, J Lawrence2, N Lindegardh3, P Rosenthal2, D Havlir2, E Charlebois2, G Dorsey2, and F Aweeka1
1Univ of California, San Francisco, Sch of Pharmacy, US; 2San Francisco Gen Hosp, Univ of California, US; and 3Faculty of Tropical Med, Mahidol Univ, Bangkok, Thailand |
| 10:30 am 133 |
Genetic Variation in Accessory Metabolic Pathways Is Associated with Extreme Efavirenz Exposure in Individuals with Impaired CYP2B6 Function
Julia di Lulio*1, M Rotger1, R Lubomirov1, L Decosterd2, C B Eap3, and A Telenti1
1Inst of Microbio, Univ Hosp Ctr and Univ of Lausanne, Switzerland; 2Univ Hosp Ctr and Univ of Lausanne, Switzerland; and 3Cery Hosp, Lausanne, Switzerland |
| 10:45 am 134 |
Long-acting TMC278, a Parenteral Depot Formulation Delivering Therapeutic NNRTI Concentrations in Preclinical and Clinical Settings
Gerben van 't Klooster*1, R Verloes1, L Baert1, F van Velsen1, M P Bouche2, K Spittaels1, J Leempoels3, P Williams1, G Kraus1, and P Wigerinck1
1Tibotec BVBA, Mechelen, Belgium; 2Johnson & Johnson Pharma R&D, Beerse, Belgium; and 3Johnson & Johnson Pharma R&D, Merksem, Belgium |
| 11:00 am 135LB |
Maraviroc (MVC) Pharmacokinetics (PK) in Blood Plasma (BP), Genital Tract (GT) Fluid and Tissue in Healthy Female Volunteers
J Dumond1, Kristine Patterson*1, A Pecha1, R Werner1, E Andrews2, B Damle2, R Tressler2, J Worsley3, K Boggess1, and A Kashuba1
1Univ of North Carolina at Chapel Hill, US; 2Pfizer Inc, New York, NY, US; and 3Pfizer Global R&D, Sandwich, Kent, UK |
| 11:15 am 136 |
The Evolution of Therapeutic Drug Monitoring in ART
Giovanni di Perri* and S Bonora
Univ of Turin, Italy |
|
